EMICRO Pharmaceutical Technology (Shanghai) Co., Ltd. is a wholly-owned subsidiary invested and established by Henan EMICRO Biomedicine Co., Ltd., and was founded in April 2020.

       The company is located in Zhangjiang High-Tech Park in Shanghai, a highland for biomedical innovation. It focuses on the research and development of innovative drugs for anti-tumor and autoimmune diseases, as well as the technical services for industrialization.

       The company is equipped with experimental instruments and equipment at the international leading level, covering a full range of detection and analysis instruments from the molecular level to the cellular level, ensuring the accuracy and reliability of experimental data. At the same time, adhering to the scientific and efficient modern management concept, the company has established a complete project management system, quality control system and talent cultivation system to ensure the smooth progress of various scientific research projects.

       The company has assembled a first-class scientific research team led by senior scientists at home and abroad and mainly composed of young scientific research backbones. The team members have rich theoretical knowledge and practical experience in the field of drug research and development for anti-tumor and autoimmune diseases, and possess the innovative ability of multi-disciplinary integration. Especially in the field of BTK inhibitor development, through the Structure-Based Drug Design (SBDD) technology platform, the company has successfully constructed a library of highly selective candidate compounds with independent intellectual property rights, and its in vitro activity and kinase selectivity indicators have reached the international advanced level.

       At present, the company has successfully established multiple promising R&D pipelines for innovative drugs, including the BTK inhibitor project, the triple-target inhibitor project, the dual-target inhibitor project, etc. In terms of innovative drug R&D technology, the company has continuously made major breakthroughs. For example, the BTK inhibitor, based on its unique molecular structure, has demonstrated excellent efficacy and safety in pre-clinical studies and early clinical trials, and is expected to bring new treatment options for patients with hematological malignancies and autoimmune diseases such as lymphoma, multiple sclerosis, and membranous nephropathy.

       The company has always adhered to the core concept of "developing biomedicine and benefiting public health", and is committed to quickly transforming cutting-edge scientific research achievements into products with clinical value and bringing them to the market. The company closely cooperates with the headquarters of Henan EMICRO Biomedicine Co., Ltd., relying on the superior resources of both sides to accelerate the R&D process of products and make every effort to promote the product launch, so as to make greater contributions to the development of the biomedical industry.